Combining CARM1 inhibitors with anti-PD-1 therapy may overcome this resistance.235 CircFGFR1 in NSCLC interacts with miR-381-3p to upregulate CXCR4, promoting tumor progression and immune evasion. Here, PDCD1 is linked to neoplasm.